| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BODIPY-FL NHS ester does not have a specific biological target; it is a fluorescent labeling reagent. The NHS ester reacts with primary amines (-NH2) on proteins, peptides, or other biomolecules to form a stable amide bond. This allows for the covalent attachment of the bright green fluorophore to the target molecule for detection and imaging applications.
|
|---|---|
| ln Vitro |
BODIPY-FL NHS ester is not evaluated for biological activity as a drug; it is a fluorescent probe. Its utility is assessed by its fluorescence properties, including excitation/emission maxima of 502/511 nm. It has high stability and is insensitive to polarity, pH, and solvent type. It is cell-permeable, making it suitable for labeling intracellular targets.
|
| ln Vivo |
BODIPY-FL NHS ester is not evaluated for in vivo biological activity as a drug; it is a fluorescent probe. It may be used in vivo for imaging applications, such as tracking labeled proteins or cells in animal models. However, the compound itself is not a therapeutic agent.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for BODIPY-FL NHS ester as a drug target. Its properties are characterized by absorbance and fluorescence spectra, quantum yield, and reactivity with amines. The efficiency of labeling can be assessed by SDS-PAGE and fluorescence imaging.
|
| Cell Assay |
There are no specific in vitro cellular assays for BODIPY-FL NHS ester as a pharmacologically active compound. As a fluorescent probe, it is used to label proteins or other biomolecules. Cells are incubated with the labeled molecule, and fluorescence is visualized by microscopy or flow cytometry. Its cell permeability allows for labeling of intracellular targets.
|
| Animal Protocol |
There are no specific in vivo animal studies for BODIPY-FL NHS ester as a pharmacologically active compound. As a fluorescent probe, it may be used for in vivo imaging studies, where the labeled molecule is administered to animals and its distribution is tracked by fluorescence imaging.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BODIPY-FL NHS ester are not applicable, as it is a fluorescent probe rather than a drug. The compound is not intended for administration as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BODIPY-FL NHS ester is not extensively reported. As a fluorescent probe, it is not intended for human therapeutic use. The compound should be handled with care in a laboratory setting. No specific toxicity data are reported.
|
| References |
|
| Additional Infomation |
BODIPY-FL NHS ester is a bright, green-fluorescent, amine-reactive probe for labeling proteins, peptides, and other biomolecules. It has excitation/emission maxima of 502/511 nm and is cell-permeable. It is used in fluorescence-based assays, including protein labeling, and is available for research purposes only.
|
| Molecular Formula |
C18H18BN3O4F2
|
|---|---|
| Molecular Weight |
389.16102
|
| Exact Mass |
389.135
|
| CAS # |
146616-66-2
|
| PubChem CID |
15410442
|
| Appearance |
Brown to red solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
838
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C2C=C3C=CC(=[N+]3[B-](F)(F)N2C(=C1)C)CCC(=O)ON4C(=O)CCC4=O
|
| InChi Key |
SDVMGNSTOAJONW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H18BF2N3O4/c1-11-9-12(2)22-15(11)10-14-4-3-13(23(14)19(22,20)21)5-8-18(27)28-24-16(25)6-7-17(24)26/h3-4,9-10H,5-8H2,1-2H3
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~321.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5696 mL | 12.8482 mL | 25.6964 mL | |
| 5 mM | 0.5139 mL | 2.5696 mL | 5.1393 mL | |
| 10 mM | 0.2570 mL | 1.2848 mL | 2.5696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
